Regeneron Pharmaceuticals and Sanofi’s anti-inflammatory drug Dupixent (dupilumab) has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
Regeneron Pharmaceuticals Inc. will invest $100 million in cancer drug developer bluebird bio Inc., and the companies will jointly develop new cell therapies for cancer.
